Bucindolol

Bucindolol

Bucindolol

Chemical compound


Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and intrinsic sympathomimetic activity in some model systems[1][2] but not in human hearts.[3][4] It was under review by the FDA in the United States for the treatment of heart failure in 2009, but was rejected due to issues pertaining to integrity of data submitted.[5]

Quick Facts Clinical data, ATC code ...

See also


References

  1. "formularyjournal.modernmedicine.com". Archived from the original on 2012-03-04.
  2. Willette RN, Mitchell MP, Ohlstein EH, Lukas MA, Ruffolo RR (January 1998). "Evaluation of intrinsic sympathomimetic activity of bucindolol and carvedilol in rat heart". Pharmacology. 56 (1): 30–6. doi:10.1159/000028179. PMID 9467185. S2CID 46848815.
  3. Bristow MR, Roden RL, Lowes BD, Gilbert EM, Eichhorn EJ (December 1998). "The role of third-generation beta-blocking agents in chronic heart failure". Clinical Cardiology. 21 (S1): I3–I13. doi:10.1002/clc.4960211303. PMC 6656140. PMID 9853189.
  4. Hershberger RE, Wynn JR, Sundberg L, Bristow MR (June 1990). "Mechanism of Action of Bucindolol in Human Ventricular Myocardium". Journal of Cardiovascular Pharmacology. 15 (6): 959–967. doi:10.1097/00005344-199006000-00014. PMID 1694919.



Share this article:

This article uses material from the Wikipedia article Bucindolol, and is written by contributors. Text is available under a CC BY-SA 4.0 International License; additional terms may apply. Images, videos and audio are available under their respective licenses.